EC’s Investigation into Illumina/Grail Merger Isn’t Stopping Anytime Soon

The European Commission will continue its investigation into Illumina’s $8 billion acquisition of Grail, the European Union General court recently ruled.

The San Diego, CA-based company said it would appeal the EU General Court ruling and noted it wanted to continue its efforts to bring Grail’s early cancer detection tests to Europe, according to a report from pharmaphorum.